The continuous augmentation and enrichment of ACP-related research is a strong positive signal in the research and development of new anti-tumour drugs; however, due to the special anti-tumour mechanisms of ACPs, their activity, toxicity and targeted efficacy need further improvement. This evidence concerns the gene NDUFAB1 and neoplasm.